<code id='F333D7C811'></code><style id='F333D7C811'></style>
    • <acronym id='F333D7C811'></acronym>
      <center id='F333D7C811'><center id='F333D7C811'><tfoot id='F333D7C811'></tfoot></center><abbr id='F333D7C811'><dir id='F333D7C811'><tfoot id='F333D7C811'></tfoot><noframes id='F333D7C811'>

    • <optgroup id='F333D7C811'><strike id='F333D7C811'><sup id='F333D7C811'></sup></strike><code id='F333D7C811'></code></optgroup>
        1. <b id='F333D7C811'><label id='F333D7C811'><select id='F333D7C811'><dt id='F333D7C811'><span id='F333D7C811'></span></dt></select></label></b><u id='F333D7C811'></u>
          <i id='F333D7C811'><strike id='F333D7C811'><tt id='F333D7C811'><pre id='F333D7C811'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:62482
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs
          Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

          YichuanCao/SipaUSAviaAPImagesGileadSciencessaidMondaythatTrodelvy,its“smart-bomb”medicinethatcombine

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Can Threads overtake X, formerly known as Twitter? Experts weigh in.

          1:37FacebookCEOMarkZuckerbergspeaksabout"NewsTab"atthePaleyCenter,Oct.25,2019,inNewYork.MarkLennihan